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OBJECTIVE—Elevated fasting glucose level is associated with
increased carotid intima-media thickness (IMT), a measure of
subclinical atherosclerosis. It is unclear if this association is
causal. Using the principle of Mendelian randomization, we
sought to explore the causal association between circulating
glucose and IMT by examining the association of a genetic risk
score with IMT.
RESEARCH DESIGN AND METHODS—The sample was
drawn from the Atherosclerosis Risk in Communities (ARIC)
study and included 7,260 nondiabetic Caucasian individuals with
IMT measurements and relevant genotyping. Components of the
fasting glucose genetic risk score (FGGRS) were selected from a
fasting glucose genome-wide association study in ARIC. The
score was created by combining ﬁve single nucleotide polymor-
phisms (SNPs) (rs780094 [GCKR], rs560887 [G6PC2], rs4607517
[GCK], rs13266634 [SLC30A8], and rs10830963 [MTNR1B]) and
weighting each SNP by its strength of association with fasting
glucose. IMT was measured through bilateral carotid ultrasound.
Mean IMT was regressed on the FGGRS and on the component
SNPs, individually.
RESULTS—The FGGRS was signiﬁcantly associated (P  0.009)
with mean IMT. The difference in IMT predicted bya1S D
increment in the FGGRS (0.0048 mm) was not clinically relevant
but was larger than would have been predicted based on ob-
served associations between the FFGRS, fasting glucose, and
IMT. Additional adjustment for baseline measured glucose in
regression models attenuated the association by about one third.
CONCLUSIONS—The signiﬁcant association of the FGGRS
with IMT suggests a possible causal association of elevated
fasting glucose with atherosclerosis, although it may be that
these loci inﬂuence IMT through nonglucose pathways.
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levated fasting glucose level is associated with
increased carotid intima-media thickness (IMT)
(1,2), a measure of subclinical atherosclerosis.
However, it is still unclear if this relation is
causal, due to unmeasured confounding by other cardio-
vascular risk factors, or due to the metabolic derange-
ments of diabetes—a disease deﬁned by fasting glucose
level.
Several recent fasting glucose genome-wide association
studies (GWAS) (3–5) and a large GWAS meta-analysis (6)
have identiﬁed multiple genetic variants with strong asso-
ciations to fasting plasma glucose level. A recent GWAS in
the Atherosclerosis Risk in Communities (ARIC) study
found ﬁve variants signiﬁcantly associated with fasting
glucose after correction for genome-wide testing (7). Con-
sistent associations for all ﬁve of the variants have been
reported in other fasting glucose GWAS (6). We demon-
strated that these variants are much more strongly asso-
ciated with fasting glucose in the normal or prediabetic
range than in the diabetic range (7).
The discovery of genetic variants reproducibly associ-
ated with fasting glucose provides the opportunity to
investigate a causal association between fasting glucose
and cardiovascular disease (CVD) using the theory of
Mendelian randomization. Because of random assortment
of alleles at the time of gamete formation, genetic variants
should not be associated with known and unknown con-
founders in association analyses. Genetic variants can also
be measured very accurately and are thus subject to little
measurement error. Finally, genetic variants are also not
susceptible to issues of reverse causality (8). Therefore,
the proxy use of single nucleotide polymorphisms (SNPs)
signiﬁcantly associated with a trait instead of the trait
itself in association analyses can help to explore a causal
association between a trait and disease (9). This technique
was recently used in a meta-analysis to examine the causal
relationship of C-reactive protein to heart disease (10). In
this paper, we applied principles of Mendelian randomiza-
tion to explore whether there is a causal relation between
fasting glucose in the nondiabetic range and subclinical
atherosclerosis. In order to reduce problems with multiple
testing, to create a genetic variable that accounted for a
substantive amount of variation in fasting glucose, and to
attempt to account for pleiotropic effects of individual
SNPs, a composite genetic risk score was used. However,
Mendelian randomization results from single SNPs associ-
ated with fasting glucose are also presented in the online
appendix available at http://diabetes.diabetesjournals.org/
cgi/content/full/db10-0839/DC1.
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The ARIC study is a multicenter prospective cohort study focused on CVD
occurrence (11). Caucasian and African American men and women aged
45–64 years at baseline were recruited from four U.S. communities. A total of
15,792 individuals participated in the baseline examination in 1987–1989. The
study was approved by the institutional review board at each center, and all
participants gave informed consent.
We included only participants with cleaned genotype information available
from the Affymetrix Genome-Wide Human SNP Array 6.0 (n  9,345 Cauca-
sians). Individuals with prevalent diabetes or missing information about
diabetes at baseline were excluded (n  829). Prevalent diabetes was deﬁned
as the presence of any of the following: a fasting serum glucose of 126 mg/dl
(7.0 mmol/l), a nonfasting serum glucose level of 200 mg/dl (11.1 mmol/l),
self-reported physician diagnosis of diabetes, or self-reported pharmacologi-
cal treatment of diabetes in the past 2 weeks. Additionally, we excluded
individuals with prevalent CVD (n  753), deﬁned as a self-reported history of
physician-diagnosed myocardial infarction or stroke or prior myocardial
infarction detected by electrocardiogram or prior self-reported cardiovascular
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FIG. 1. Distribution of the FGGRS (A) and mean fasting glucose by FGGRS (B). FGGRS  {[(no. of rs780094 risk alleles)  0.0463]  [(no. of
rs560887 risk alleles)  0.0685]  [(no. of rs4607517 risk alleles)  0.0673]  [(no. of rs13266634 risk alleles)  0.0433]  [(no. of rs10830963
risk alleles)  0.0796]}/0.061. To create these plots, all individuals with an FGGRS <1 were included in the ﬁrst category, all individuals with a
FGGRS >1 but <2 were included in the second category, etc. Means of fasting glucose in B are adjusted for age, sex, and ARIC study center and
presented with 95% CI.
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fasting at least8ha tbaseline (n  125) and anyone with either a missing or
extremely large (greater than 1.7 mm) IMT measurement at baseline (n 
378). After all exclusions, there were 7,260 individuals in the sample.
Phenotypic measurements. Glucose was measured in serum by a hexoki-
nase/glucose-6-phosphate dehydrogenase method on a Coulter DACOS device
(Beckman Coulter, Fullerton, CA). BMI was calculated from participants’
heights and weights measured in scrub suits. Carotid artery IMT was
determined by high-resolution B-mode ultrasound, as described previously
(12,13). Trained technicians scanned the extracranial carotid arteries bilater-
ally, and scans were read according to a standardized protocol at a centralized
facility. Missing measurements were imputed from sex- and race-speciﬁc
multivariate linear models of mean IMT, as described elsewhere (2). The
variable used for analysis was the average IMT of the far wall across three
segments in the left and right carotid arteries: carotid bifurcation, common
carotid, and internal carotid (six sites total).
Genotyping. ARIC GWAS genotyping has been described in detail previously
(7). SNPs were selected for inclusion in the fasting glucose genetic risk
score (FGGRS) based on ﬁve regions of the genome that exceeded a
genome-wide threshold for signiﬁcance (14) in a previously-published
GWAS of baseline fasting glucose among nondiabetic subjects in the ARIC
study (7). A single SNP from each region was selected for inclusion in the
score based on the SNP that reached the greatest level of signiﬁcance for the
region in fasting glucose or diabetes GWAS meta-analyses (6,15). The selected
SNPs were rs780094 (GCKR), rs560887 (G6PC2), rs4607517 (GCK),
rs13266634 (SLC30A8), and rs10830963 (MTNR1B). In cases where the
selected SNP was imputed (rs4607517, rs13266634), the most likely predicted
genotype was used.
Statistical analysis. All analyses were performed in SAS v9.1 (Cary, NC). To
create the FGGRS, the number of risk (glucose-increasing) alleles from SNPs
rs10830963, rs560887, rs4607517, rs780094, and rs13266634 was summed. To
account for the differing effect sizes of the SNPs, the number of risk alleles
from each SNP was multiplied by the predicted effect size from regression of
baseline fasting glucose on that SNP (7). The total score was then divided by
the average effect size to rescale the score with a possible range of 0–10 (the
range of the possible number of glucose-increasing alleles for each individ-
ual). An equation for the calculation of the risk score can be found in Fig. 1.
Untransformed IMT was regressed on the FGGRS, and both variables were
modeled continuously. Regression was weighted by the number of observed
(versus imputed) IMT measurements per person. Predicted associations
between FGGRS and IMT were estimated by multiplying the observed
difference in baseline fasting glucose for 1 SD increase of FGGRS (0.0854
mmol/l) by the observed difference in IMT per 1 SD increase in baseline fasting
glucose (0.0103 mm per 0.50 mmol/l of glucose). The predicted association
between FGGRS and IMT was then compared with the observed association
between FGGRS and IMT for the same 1 SD increase in FGGRS.
RESULTS
Of the 7,260 individuals in the study sample, 44.5% were male.
The average age in the study sample was 53.9 years, and the
average BMI was 26.5 kg/m
2. The mean fasting glucose
measurement was 5.5 mmol/l. Figure 1A demonstrates the
distribution of FGGRS in the sample. The FGGRS was
normally distributed with a mean of 4.6 and an SD of 1.4.
Figure 1B shows the mean serum fasting glucose by FGGRS
category, adjusted for age, sex, and ARIC study center.
Adjusted mean fasting glucose increased for each successive
category of the FGGRS except between categories 8 and 9 in
which the mean decreased by 0.04 mmol/l.
Table 1 shows the associations of IMT with fasting
glucose and the FGGRS. The FGGRS was very signiﬁcantly
associated with fasting glucose in ARIC (P  1.1  10
54).
Adjusted for age, sex, and study center, the FGGRS
accounted for an additional 2.9% of the variance in fasting
glucose. The FGGRS was signiﬁcantly associated (P 
0.009) with mean IMT, although the difference in IMT
predicted by 1 SD increment of the FGGRS (0.0048 mm)
was small. The IMT and FGGRS association was attenu-
ated by approximately one third (0.0032 mm) when
fasting glucose was also included as a covariate in the
regression model. Supplementary Table 1 in the online
appendix details the association of individual SNPs in the
FGGRS with fasting glucose. No single SNP accounted for
more than an additional 0.86% of the variance in fasting
glucose. Supplementary Table 2 lists the associations of
the individual SNPs in the FGGRSs with IMT before and
after adjustment for baseline fasting glucose. Only one
SNP (rs560887) was signiﬁcantly (P  0.0055) associated
with IMT when analyzed individually.
To further investigate the association between IMT and
the FGGRS, we undertook several sensitivity analyses.
Excluding individuals with a FGGRS 1o r8.8 did not
attenuate the association (0.0049 mm, P  0.009).
Excluding individuals near the fasting glucose threshold
for diabetes at baseline (fasting glucose 6.66 mmol/l,
individuals who might be at very high risk of shortly
developing diabetes or who may have been misclassiﬁed
as not having diabetes) attenuated the association only
slightly (0.0046 mm, P  0.01). Adjusting the regres-
sion model for 10 principal components derived from
GWAS data to account for differences in genetic ancestry
within the sample did not attenuate the association (
0.0048 mm, P  0.009). Using a different FGGRS derived
from the results of the Dupuis et al. (6) GWAS meta-
analysis of fasting glucose, which included 16 SNPs and
was weighted based on the effect sizes taken from the
meta-analysis replication sample, attenuated the associa-
tion of score and IMT slightly (P  0.025).
Figure 2 compares the observed association of the
FGGRS and IMT with the predicted association. The
observed association (0.0048 mm of IMT per 1.4 unit
difference in score) was over two times larger than the
predicted association (0.0018 mm of IMT per 1.4 unit
difference in score). Supplementary Fig. 1A–E in the online
appendix compares observed with predicted associations
for the ﬁve component SNPs of the FGGRS. For all SNPs
(except rs780094, a SNP with known opposing pleiotropic
TABLE 1
Associations of IMT with measured fasting glucose and the FGGRS
Models* adjusted for age, sex, study center
Model* additionally adjusted
for baseline fasting glucose
Association per 1 SD
increment (1.4) in
FGGRS P
Association per 1 SD
increment (0.50
mmol/l) in measured
fasting serum glucose P
Association per 1 SD
increment (1.4) in
FGGRS P
Baseline fasting
glucose (mmol/l) 0.0854 (SE 0.0054) 1.07E54 ————
IMT (mm) 0.0048 (SE 0.0019) 0.009 0.0103 (SE 0.0019) 8.01E8 0.0032 (SE 0.0019) 0.09
*Linear regression.
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observed association with IMT was larger than that pre-
dicted—although the magnitude of the difference varied
considerably between SNPs.
DISCUSSION
In this analysis we created an FGGRS that accounted for
2.9% of the variance in fasting glucose among nondiabetic
adults after adjustment for age, sex, and study center. The
FGGRS was signiﬁcantly and positively associated with
carotid IMT. Inclusion of measured baseline glucose in the
model attenuated the association between the risk score
and IMT by 33% (P  0.09). Similar results were seen for
individual SNPs used to construct the risk score except for
rs780094, a SNP having demonstrated opposing associa-
tions with other cardiovascular risk factors including
triglycerides, and HDL, LDL, and VLDL cholesterol (16,17).
The statistical signiﬁcance of the association between
the FGGRS and IMT offers some support for the hypothe-
sis that fasting glucose is causally related to the develop-
ment of subclinical atherosclerosis. Additionally, the fact
that the FGGRS remains modestly associated with IMT
after the inclusion of fasting glucose in the model and the
larger observed than predicted association between the
FGGRS and IMT suggests that the risk score provides
additional information to a single measure of fasting
glucose. We hypothesize the FGGRS gives more informa-
tion than a single measurement of fasting glucose because
it provides information about cumulative lifetime expo-
sure to fasting glucose (because those with a high FGGRS
would be expected, on average, to have slightly higher
levels of fasting glucose over much of the life span). The
FGGRS also may give more information because of possi-
ble pleiotropic effects of the SNPs.
It is difﬁcult to use Mendelian randomization and this
FGGRS to completely discriminate the effects of glucose
level from other cardiovascular risk factors on IMT be-
cause of the possible pleiotropic effects of SNPs in the
FGGRS. However, the signiﬁcant association of the score
(as opposed to just the component SNPs) with IMT is
unlikely to be due entirely to pleiotropy because it is not
expected that all the SNPs used to construct the score
would have similar pleiotropic associations with IMT.
Therefore, a causal association between fasting glucose
and IMT is a plausible explanation for the signiﬁcant
association of IMT and the FGGRS. The larger than
predicted associations between the component SNPs and
IMT also suggest that G6PC2 and GCK should be studied
further to learn about other potential pathways through
which these SNPs may alter IMT.
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